733P - Testicular cancer: Trends in incidence and demographics from 23,214 cases in California from 2000-2020

Background

The incidence of testicular cancer (TC) has been rising over the past five decades for reasons currently unknown. As marijuana use is believed to increase the risk of TC, we sought to assess recent trends in incidence rates in California to see if further changes might be due to recent policy initiatives such as marijuana legalization.

Methods

Men diagnosed with TC between 2000 and 2020 were identified through the California Cancer Registry database (n = 23,214). Cancer occurrence by age and race/ethnicity were examined. Incidence rates by year of diagnosis and race/ethnicity were calculated, and age-adjusted to the 2000 US Standard Population.

Results

The incidence of TC among all racial/ethnic groups has been rising in California between 2000 and 2020. In particular, incidence has been rising at faster pace among Hispanic men and Asian/Pacific Islander men during this period. Among Hispanic men, the incidence rate was 4.2/100,000 in 2000 and rose to 6.7/100,000 in 2020. Similarly, the incidence rate for Asian/Pacific Islander men was 2.0/100,000 in 2000, decreased to 1.2/100,000 in 2002 and rose to 2.5/100,000 in 2020. This increasing trend for incidence rates is mainly observed among men below age 40. Table: 733P

Incidence rates for male malignant testicular cancer in California, 2000-2020

Rates are per 100,000 and age-adjusted to 2000 US Std Population (19 age groups – Census P25-1130) standard.

Conclusions

This is one of the largest epidemiological studies on TC. The incidence of TC has been rising in California since 2000, particularly among Hispanic and Asian/Pacific Islander men. The rise in TC rates started prior to the year of marijuana legalization (2015), thus suggesting other factors may be leading to rising incidence rates.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

A. Rezazadeh Kalebasty: Financial Interests, Personal, Stocks/Shares: ECOM Medical; Financial Interests, Personal, Advisory Role: AstraZeneca, Bayer, Bristol Myers Squibb, EMD Serono, Exelixis, Immunomedics, Genentech, Gilead Sciences, Novartis, Pfizer; Financial Interests, Personal, Speaker’s Bureau: Amgen, Astellas Medivation, AVEO, AstraZeneca, Bristol Myers Squibb, Eisai, EMD Serono, Exelixis, Genentech/Roche, Gilead Sciences, Janssen, Merck, Myocant Sciences, Novartis, Pfizer, Sanofi, Seattle Genetics; Financial Interests, Personal, Research Funding: Astellas Pharma, AstraZeneca, Bavarian Nordic, Bayer, Beyond Spring, BioClin Therapeutics, Bristol Myers Squibb, Clovis Oncology, Eisai, Epizy, Exelixis, Genentech, Immunomedics, Janssen, Macrogenics, Seattle Genetics; Financial Interests, Personal, Other: Astellas Medivation, AstraZeneca, Bayer, Eisai, Exelixis, Genentech, Janssen, Novartis, Pfizer, Prometheus Laboratories. All other authors have declared no conflicts of interest.